Amgen, Adaptive Biotechnologies Partner on Drug Discovery for COVID-19

Apr 02, 2020

|

NEW YORK – Amgen and Adaptive Biotechnologies said on Thursday that they are collaborating to discover and develop human antibody-based treatments for COVID-19.

The companies have signed a memorandum of understanding and plan to execute a collaboration and license agreement, the terms of which will not be disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Menu

Amgen, Adaptive Biotechnologies Partner on Drug Discovery for COVID-19

To read the full story....

Breaking News

Molecular Changes Wrought by Spaceflight Explored in Newly Published Studies

Recurrent SARS-CoV-2 Virus Mutations Do Not Increase Transmissibility, Study Finds

Somalogic Closes $121M Series A Funding

Pediatric Brain Tumor Proteomics Highlight Possible Treatment Targets, Biomarkers

In Brief This Week: Fluidigm, Centogene, Ginkgo Bioworks, Applied DNA Sciences, More

FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

The Scan

High Numbers Reported for Russian Vaccine

Masterpiece Microbiome

Limited Trust

Nucleic Acids Research Papers on Aging Atlas, Human Metagenomes, Drug Repositioning

What's Popular?

In Brief This Week: Fluidigm, Centogene, Ginkgo Bioworks, Applied DNA Sciences, More

FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

Startup Angstrom Bio Plans Saliva-Based COVID-19 Nucleic Acid Test on Nanopore Sequencing Platform

Tempus Gets CE Mark for xT Tumor Sequencing Assay

Twist Bioscience Fiscal Q4 Revenues More Than Double

Sponsorships